{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:20:52Z","timestamp":1769505652434,"version":"3.49.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"am","delay-in-days":295,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA053443"],"award-info":[{"award-number":["DA053443"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA006420"],"award-info":[{"award-number":["AA006420"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA026999"],"award-info":[{"award-number":["AA026999"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA028549"],"award-info":[{"award-number":["AA028549"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["T32 AA007456"],"award-info":[{"award-number":["T32 AA007456"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","award":["MISP59371"],"award-info":[{"award-number":["MISP59371"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.neuropharm.2023.109685","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T16:31:06Z","timestamp":1691857866000},"page":"109685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1841-9139","authenticated-orcid":false,"given":"Jessica M.","family":"Illenberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5839-3332","authenticated-orcid":false,"given":"Francisco J.","family":"Flores-Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Pascasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Matzeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-5885","authenticated-orcid":false,"given":"R\u00e9mi","family":"Martin-Fardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109685_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainres.2009.09.106","article-title":"Lateral hypothalamic orexin\/hypocretin neurons: a role in reward-seeking and addiction","volume":"1314","author":"Aston-Jones","year":"2010","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109685_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/00952990.2011.596982","article-title":"Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial","volume":"37","author":"Back","year":"2011","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2023.109685_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00213-020-05750-2","article-title":"A buprenorphine-validated rat model of opioid use disorder optimized to study sex difference in vulnerability to relapse","volume":"238","author":"Bakhti-Suroosh","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"issue":"36","key":"10.1016\/j.neuropharm.2023.109685_bib4","doi-asserted-by":"crossref","first-page":"11215","DOI":"10.1523\/JNEUROSCI.6096-08.2009","article-title":"Orexin A\/hypocretin-1 selectively promotes motivation for positive reinforcers","volume":"29","author":"Borgland","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109685_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2023.109685_bib6","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1126\/science.8099761","article-title":"Modulation of cocaine self-administration in th rat through D-3 dopamine receptors","volume":"260","author":"Caine","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109685_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.08.005","article-title":"A sleeping giant: suvorexant for the treatment of alcohol use disorder","volume":"1731","author":"Campbell","year":"2020","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109685_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-012-2902-y","article-title":"Role of orexin\/hypocretin in conditioned sucrose-seeking in rats","volume":"226","author":"Cason","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109685_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.physbeh.2010.03.009","article-title":"Role of orexin\/hypocretin in reward-seeking and addiction: implications for obesity","volume":"100","author":"Cason","year":"2010","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2023.109685_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0006-8993(87)90908-5","article-title":"Self-administration of morphine into the lateral hypothalamus in the mouse","volume":"416","author":"Cazala","year":"1987","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/2589977515666221108093830","article-title":"Daridorexant, a recently approved dual orexin receptor antagonist (DORA) in the treatment of insomnia","volume":"15","author":"Chakraborty","year":"2022","journal-title":"Curr. Drug. Res. Rev."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109685_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.mcna.2018.02.012","article-title":"Sleep management among patients with substance use disorders","volume":"102","author":"Chakravorty","year":"2018","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.neuropharm.2023.109685_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109685_bib15","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1111\/jcmm.13266","article-title":"Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction","volume":"21","author":"Chiang","year":"2017","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2023.109685_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2020.101332","article-title":"Effects of orexin receptor antagonism on human sleep architecture: a systematic review","volume":"53","author":"Clark","year":"2020","journal-title":"Sleep Med. Rev."},{"issue":"14","key":"10.1016\/j.neuropharm.2023.109685_bib18","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109685_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biopsych.2007.02.002","article-title":"Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse","volume":"63","author":"Dayas","year":"2008","journal-title":"Biol. Psychiatr."},{"issue":"1601","key":"10.1016\/j.neuropharm.2023.109685_bib20","first-page":"97","volume":"62","author":"Dayvigo","year":"2020","journal-title":"Med. Lett. Drugs Ther."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109685_bib21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1213\/ANE.0000000000000672","article-title":"Chronic opioid use and central sleep apnea","volume":"120","author":"Denis","year":"2015","journal-title":"Anesth. Analg."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109685_bib22","first-page":"33","article-title":"The effect of opioids on sleep architecture","volume":"3","author":"Dimsdale","year":"2007","journal-title":"J. Clin. Sleep Med."},{"issue":"15","key":"10.1016\/j.neuropharm.2023.109685_bib23","first-page":"1624","article-title":"CDC guidelines for prescribing opioids for chronic pain-United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"},{"issue":"28","key":"10.1016\/j.neuropharm.2023.109685_bib24","first-page":"1","article-title":"Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 antagonism","volume":"8","author":"Dugovic","year":"2014","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109685_bib25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1124\/mol.119.119107","article-title":"Bidirectional relationship between opioids and disrupted sleep: putative mechanisms","volume":"98","author":"Eacret","year":"2020","journal-title":"Mol. Pharmacol."},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2023.109685_bib26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/FBP.0b013e3283644d15","article-title":"Escalation of drug self-administration as a hallmark of persistent addiction liability","volume":"24","author":"Edwards","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109685_bib27","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00213-019-05371-4","article-title":"PSPH-18-00526: effect of a dual orexin receptor antagonist (DORA-12) on sleep and event-related oscillations in rats exposed to ethanol vapor during adolescence","volume":"237","author":"Ehlers","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109685_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2022.1085882","article-title":"Alternative use of suvorexant (Belsomra\u00ae) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence","volume":"16","author":"Flores-Ramirez","year":"2022","journal-title":"Front. Behav. Neurosci."},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109685_bib29","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/s41386-019-0420-x","article-title":"The role of orexin-1 receptor signaling in demand for the opioid fentanyl","volume":"44","author":"Fragale","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109685_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12946","article-title":"Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system","volume":"26","author":"Fragale","year":"2020","journal-title":"Addiction Biol."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109685_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12822","article-title":"Sex differences in oral oxycodone self-administration and stress-primed reinstatement in rats","volume":"25","author":"Fulenwider","year":"2020","journal-title":"Addiction Biol."},{"issue":"8","key":"10.1016\/j.neuropharm.2023.109685_bib32","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1523\/JNEUROSCI.23-08-03106.2003","article-title":"Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal","volume":"23","author":"Georgescu","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109685_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2202-14-90","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Gotter","year":"2013","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109685_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2202-15-109","article-title":"Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators","volume":"15","author":"Gotter","year":"2014","journal-title":"BMC Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejps.2013.02.006","article-title":"The applications of Vitamine E TPGS in drug delivery","volume":"49","author":"Guo","year":"2013","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109685_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/adb.12236","article-title":"Orexin A-mediated AKT signaling in the dentate gyrus contributes to the acquisition, expression and reinstatement of morphine-induced conditioned place preference","volume":"21","author":"Guo","year":"2016","journal-title":"Addiction Biol."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109685_bib37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin receptor antagonists as emerging treatments for psychiatric disorders","volume":"36","author":"Han","year":"2020","journal-title":"Neurosci. Bull."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109685_bib39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature04071","article-title":"A role for the lateral hypothalamic orexin neurons in reward seeking","volume":"437","author":"Harris","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109685_bib40","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.addbeh.2014.05.025","article-title":"Sleep disturbances and pain among individuals with prescription opioid dependence","volume":"39","author":"Hartwell","year":"2014","journal-title":"Addict. Behav."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109685_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2004.02.001","article-title":"Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment","volume":"74","author":"Hernandez-Avila","year":"2004","journal-title":"Drug Alcohol Depend."},{"issue":"47","key":"10.1016\/j.neuropharm.2023.109685_bib42","article-title":"Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence","volume":"6","author":"Hollander","year":"2012","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109685_bib43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1748-1716.2009.02032.x","article-title":"Histamine1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep\/wake states","volume":"198","author":"Hondo","year":"2010","journal-title":"Acta Physiol."},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109685_bib44","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/pm\/pny295","article-title":"Individuals with chronic pain who misuse prescription opioids report sex-based differences in pain and opioid withdrawal","volume":"20","author":"Huhn","year":"2019","journal-title":"Pain Med."},{"key":"10.1016\/j.neuropharm.2023.109685_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1127735","article-title":"Suvorexant, an FDA-approved dual orexin receptor antagonist reduces oxycodone self-administration and condition reinstatement in male and female rats","volume":"14","author":"Illenberger","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2023.109685_bib46","article-title":"The physiological role of orexin\/hypocretin neurons in the regulation of sleep\/wakefulness and neuroendocrine functions","volume":"4","author":"Inutsuka","year":"2013","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109685_bib47","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41386-020-0619-x","article-title":"Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?","volume":"45","author":"James","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","article-title":"Opioids excite dopamine neurons by hyperpolarization of local interneurons","volume":"12","author":"Johnson","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109685_bib49","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1476-5381.2010.01088.x","article-title":"Discrete cue-conditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin receptors","volume":"162","author":"Jupp","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109685_bib50","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00213-020-05479-y","article-title":"Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats","volume":"237","author":"Kimbrough","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109685_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","article-title":"Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement","volume":"87","author":"Koob","year":"2020","journal-title":"Biol. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109685_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pharmrev.120.000083","article-title":"Drug Addiction: hyperkatifeia\/negative reinforcement as a framework for medications development","volume":"73","author":"Koob","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"5335","key":"10.1016\/j.neuropharm.2023.109685_bib53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.278.5335.52","article-title":"Drug abuse: hedonic homeostatic dysregulation","volume":"278","author":"Koob","year":"1997","journal-title":"Science"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2023.109685_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.13011su1c","article-title":"Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system","volume":"74","author":"Krystal","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109685_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.smrv.2016.09.004","article-title":"Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis","volume":"35","author":"Kuriyama","year":"2016","journal-title":"Sleep Med. Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib56","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.36076\/ppj.2017.s92","article-title":"Responsible, safe, and effective prescription opioid for chronic non-cancer pain: American society of interventional pain physicians (ASIPP) guidelines","volume":"20","author":"Manchikanti","year":"2017","journal-title":"Pain Physician"},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109685_bib57","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.5665\/sleep.2232","article-title":"The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors","volume":"35","author":"Mang","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109685_bib58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1369-1600.2012.00480.x","article-title":"N-(2-methyl-6-benzoxazolyl)-N\u2019-1,5-naphthyridin-4-yl urea (SB334867), a hypocretin receptor-1 antagonist, preferentially prevents ethanol seeking: comparison with natural reward seeking","volume":"19","author":"Martin-Fardon","year":"2012","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2023.109685_bib59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/adb.12441","article-title":"Differential role of hypothalamic orexin\/hypocretin neurons in reward seeking motivated by cocaine versus palatable food","volume":"23","author":"Martin-Fardon","year":"2018","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2023.109685_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107906","article-title":"Targeting the orexin system for prescription opioid use disorder: orexin-1 receptor blockade prevents oxycodone taking and seeking in rats","volume":"164","author":"Matzeu","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109685_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146461","article-title":"Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil","volume":"1731","author":"Mohammadkhani","year":"2020","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109685_bib62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.alcohol.2009.07.002","article-title":"Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol-preferring Sprague-Dawley rats","volume":"43","author":"Moorman","year":"2009","journal-title":"Alcohol"},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109685_bib63","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/00952990.2018.1454934","article-title":"Sex differences in daily life stress and craving in opioid-dependent patients","volume":"44","author":"Moran","year":"2018","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2023.109685_bib64","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1523\/JNEUROSCI.2761-05.2006","article-title":"Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine","volume":"26","author":"Narita","year":"2006","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109685_bib65","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0022-3565(25)38246-7","article-title":"Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats","volume":"265","author":"Negus","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"18","key":"10.1016\/j.neuropharm.2023.109685_bib66","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1111\/bph.15520","article-title":"Paradoxical changes in brain reward status during oxycodone self-administration in a novel test of the negative reinforcement hypothesis","volume":"178","author":"Nguyen","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib67","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drugalcdep.2005.08.011","article-title":"Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients","volume":"82","author":"Peles","year":"2005","journal-title":"Drug Alcohol Depend."},{"issue":"23","key":"10.1016\/j.neuropharm.2023.109685_bib68","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109685_bib69","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109685_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13665","article-title":"The orexin story, sleep and sleep disturbances","volume":"31","author":"Pizza","year":"2022","journal-title":"J. Sleep Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib71","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/adb.12323","article-title":"Individual differences in orexin 1 receptor modulation of motivation for the opioid remifentanil","volume":"22","author":"Porter-Stransky","year":"2017","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2023.109685_bib72","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1871527311312010017","article-title":"Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets","volume":"12","author":"Rehni","year":"2013","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109685_bib73","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0165-0173(93)90013-P","article-title":"The neural basis of drug craving: an incentive-sensitization theory of addiction","volume":"18","author":"Robinson","year":"1993","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2023.109685_bib74","article-title":"Alteration of orexin-A and PKC alpha in the postmortem brain of pure-opioid and multi-drug abusers","volume":"83","author":"Sadat-Shirzai","year":"2020","journal-title":"Neuropeptides"},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109685_bib75","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/npp.2014.293","article-title":"Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats","volume":"40","author":"Schmeichel","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109685_bib76","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00008877-199905000-00001","article-title":"Differential expression of response-disruptive and somatic indices of opiate withdrawal during the initiation and development of opiate dependence","volume":"10","author":"Schulteis","year":"1999","journal-title":"Behav. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109685_bib77","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1460-9568.2012.08013.x","article-title":"Orexin\/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking","volume":"35","author":"Smith","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"21","key":"10.1016\/j.neuropharm.2023.109685_bib78","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1523\/JNEUROSCI.5223-05.2006","article-title":"Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women","volume":"26","author":"Smith","year":"2006","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109685_bib79","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1460-9568.2009.06844.x","article-title":"Orexin\/hypocretin signaling at the OX1 receptor regulates cue-elicited cocaine-seeking","volume":"30","author":"Smith","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109685_bib81","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"issue":"447","key":"10.1016\/j.neuropharm.2023.109685_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4953","article-title":"Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy","volume":"10","author":"Thannickal","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2023.109685_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841873","article-title":"Sex- and dose-dependent differences in the development of an addiction-like phenotype following extended-access fentanyl self-administration","volume":"13","author":"Towers","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109685_bib84","series-title":"2019 NSDUH Annual National Report","year":"2020"},{"key":"10.1016\/j.neuropharm.2023.109685_bib85","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1101\/lm.050187.119","article-title":"Acute ovarian hormone treatment in freely cycling female rats regulates distinct aspects of heroin seeking","volume":"27","author":"Vazquez","year":"2020","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuropharm.2023.109685_bib86","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109685_bib87","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-Like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109685_bib88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.smrv.2006.03.006","article-title":"Opioids, sleep architecture and sleep-disordered breathing","volume":"11","author":"Wang","year":"2007","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109685_bib89","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1378\/chest.128.3.1348","article-title":"Central sleep apnea in stable methadone maintenance treatment patients","volume":"128","author":"Wang","year":"2006","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109685_bib90","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1526-4637.2007.00343.x","article-title":"Sleep-disordered breathing and chronic opioid therapy","volume":"9","author":"Webster","year":"2008","journal-title":"Pain Med."},{"issue":"4049","key":"10.1016\/j.neuropharm.2023.109685_bib91","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1126\/science.177.4049.616","article-title":"Neuroanatomical correlates of morphine dependence","volume":"177","author":"Wei","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109685_bib92","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","article-title":"Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes","volume":"38","author":"Willie","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109685_bib93","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0896-6273(02)00965-0","article-title":"Brain reward circuitry: insights from unsensed incentives","volume":"36","author":"Wise","year":"2002","journal-title":"Neuron"},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2023.109685_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2007.09.023","article-title":"Non-prescribed use of pain relievers among adolescents in the United States","volume":"94","author":"Wu","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109685_bib95","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.pbb.2007.01.008","article-title":"Gender and stimulus difference in cue-induced responses in abstinent heroin users","volume":"86","author":"Yu","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109685_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107978","article-title":"Female and male rats readily consume and prefer oxycodone to water in a chronic, continuous access, two-bottle oral voluntary paradigm","volume":"167","author":"Zanni","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109685_bib97","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1677\/joe.1.06960","article-title":"Mu opioid receptor and orexin\/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal","volume":"191","author":"Zhou","year":"2006","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.neuropharm.2023.109685_bib98","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.physbeh.2014.11.002","article-title":"Individual differences in gene expression of vasopressin, D2 receptor, POMC and orexin: vulnerability to relapse in heroin-seeking in rats","volume":"139","author":"Zhou","year":"2015","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109685_bib99","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ijo.2017.276","article-title":"Neuromodulation of orexin neurons reduces diet-induced adiposity","volume":"42","author":"Zink","year":"2018","journal-title":"Int. J. Obes."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:25:59Z","timestamp":1758439559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823002757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":97,"alternative-id":["S0028390823002757"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109685","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109685"}}